These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12556213)

  • 1. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
    Fujii N; Nakashima H; Tamamura H
    Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
    Kanbara K; Sato S; Tanuma J; Tamamura H; Gotoh K; Yoshimori M; Kanamoto T; Kitano M; Fujii N; Nakashima H
    AIDS Res Hum Retroviruses; 2001 May; 17(7):615-22. PubMed ID: 11375057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists.
    Tamamura H; Fujii N
    Curr Drug Targets Infect Disord; 2004 Jun; 4(2):103-10. PubMed ID: 15180458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe use of the CXCR4 inhibitor ALX40-4C in humans.
    Doranz BJ; Filion LG; Diaz-Mitoma F; Sitar DS; Sahai J; Baribaud F; Orsini MJ; Benovic JL; Cameron W; Doms RW
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):475-86. PubMed ID: 11350661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H; Otaka A; Fujii N
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CXCR4 in HIV cell-entry inhibition.
    Steen A; Schwartz TW; Rosenkilde MM
    Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of selective antagonists against an HIV second receptor].
    Tamamura H
    Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
    Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
    J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
    Tamamura H; Fujii N
    Expert Opin Ther Targets; 2005 Dec; 9(6):1267-82. PubMed ID: 16300475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4].
    Kanbara K; Fujii N; Nakashima H
    Kansenshogaku Zasshi; 2000 Mar; 74(3):237-44. PubMed ID: 10783578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
    Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
    Murakami T; Kumakura S; Yamazaki T; Tanaka R; Hamatake M; Okuma K; Huang W; Toma J; Komano J; Yanaka M; Tanaka Y; Yamamoto N
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2940-8. PubMed ID: 19451305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New advances in HIV entry inhibitors development.
    Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.
    Doranz BJ; Grovit-Ferbas K; Sharron MP; Mao SH; Goetz MB; Daar ES; Doms RW; O'Brien WA
    J Exp Med; 1997 Oct; 186(8):1395-400. PubMed ID: 9334380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-receptor antagonists as HIV-1 entry inhibitors.
    Shaheen F; Collman RG
    Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
    De Clercq E
    Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
    Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
    Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.